We’re seeking to advance the standard for precision gene therapy

By deploying advanced computational methods and unbiased screening directly in NHP's - we're mapping the future of delivery for genetic medicines. Designed to accurately target tissues and reduce unwanted interactions, our technology aims to minimize the risks of immunogenicity and toxicity, delivering the payload exactly where it's needed.

Our one-time gene therapy candidates are designed to fundamentally change how many diseases are treated.

Our proprietary platforms enable massively-paralleled and unbiased screening of AAV capsid variant libraries directly in non-human primates (NHPs)

Identify Disease- and Target-specific Substructure

Select Optimal Route for Clinical Administration (RoA)

Screen for Novel Tissue- and Cell-specific Capsids via Optimal ROA in NHPs

Engineer Specific Payload Expression Using Proprietary Promoters and Regulatory Elements

We identify novel AAV capsid variants with substructure- and cell-type specificity matched to optimal routes of administration (RoAs)

Deep Brain

Ependyma

Ear

Pan-Neuronal

Eye

muscle

Heart

kidney

We’re seeking to advance the standard for precision gene therapy

Our one-time gene therapy candidates are designed to fundamentally change how many diseases are treated.

Our proprietary platforms enable massively-paralleled and unbiased screening of AAV capsid variant libraries directly in non-human primates (NHPs)

We identify novel AAV capsid variants with substructure- and cell-type specificity matched to optimal routes of administration (RoAs)

Our novel AAV capsid variants have the potential to unlock significant clinical benefit and commercial upside